The UTS Translational Cancer Research Group (TCRG) directed by Dr Rosetta Martiniello-Wilks has a proven track record in taking basic science discoveries and translating them into the clinic. TCRG and their collaborators focus on the development of innovative, non-invasive molecular tests for the early detection/prognosis of conventional and lethal prostate cancer (PCa) allowing for more informed and personalised clinical care. This research utilises circulating nanovesicles (exosomes) as a liquid biopsy target for cancer diagnosis. Another TCRG research focus is the development of 'Advanced Cell and Gene Medicines' for prostate cancer metastases based on novel viral vector delivery, non-viral delivery (including cell therapies) and non-toxic pro-drug converting enzyme gene technologies that kill cancer. To make this research a reality, Dr Wilks as Principal or co-investigator has raised over $17million in research and infrastructure funding from the Prostate Cancer Foundation of Australia (PCFA), Movember, Cancer Institute NSW/Sydney Vital, NHMRC, US Army Department of Defence, National Cancer Institute USA, Australian Cancer Research Fund, Rebecca L Cooper Medical Research Foundation. Highlights of this collaborative research include: 6 national/international patents with Dr Wilks listed as an Inventor; Therapeutic Goods Administration CTX approval of a Phase 1 clinical trial FP253 gene therapy for prostate cancer (registered NCT00625430; www.clinicaltrials.gov); a CSIRO Chairman’s Medal Platinum Nomination; development of a CSIRO spin-out company Broadvector Limited.